Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Pathological Predictors of Lymph Node Involvement in Submucosal Gastric Carcinoma: A Retrospective Analysis of Long-Term Outcome

GABRIELLA NESI, GIANCARLO BASILI, LUCIA ROBERTA GIRARDI, ANDREA MANETTI, GIANCARLO BILIOTTI and ALESSANDRO BARCHIELLI
In Vivo March 2009, 23 (2) 337-341;
GABRIELLA NESI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gabriella.nesi@unifi.it
GIANCARLO BASILI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUCIA ROBERTA GIRARDI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREA MANETTI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIANCARLO BILIOTTI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALESSANDRO BARCHIELLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The incidence of nodal metastasis in early gastric cancer (EGC) ranges from 5.7 to 13% . Since most patients with EGC do not have lymph node metastasis, the validity of extended nodal dissection has been questioned. Patients and Methods: Clinicopathological data of 116 patients with EGC, all undergoing D2 lymphadenectomy, were analysed. Patients with or without lymph node metastases were compared in relation to age and gender distribution, tumour histopathology and 10-year prognosis. Results: The overall rate of nodal metastasis was 9.5% . The invasion of submucosa, Laurén's diffuse type, a diameter greater than 3 cm, and Pen-A and Pen-B growth patterns were significantly associated with an increased incidence of lymph node metastasis. On multivariate analysis, the diffuse type was an independent risk factor for lymph node involvement, regardless of tumour size and growth pattern (p=0.007). Ten-year survival analysis showed no significant correlation with lymph node metastasis (86.5% vs. 71.6%). Conclusion: Submucosal carcinomas of intestinal type, under 2 cm in size, are eligible for minimally invasive surgery while, in diffuse-type carcinomas over 2 cm, standard surgery with D2 lymphadenectomy is recommended.

  • Early gastric cancer
  • lymph node metastasis
  • lymphadenectomy
  • prognosis

In 1962, the Japanese Society of Gastroenterological Endoscopy defined early gastric cancer (EGC) as an adenocarcinoma confined to the mucosa and the submucosa, irrespective of lymph node metastasis (1). Due to an aggressive screening practice, this tumour is most commonly diagnosed in Japan, where it represents more than 50% of all gastric cancers (2). In Western countries, the incidence of EGC has gradually increased over recent decades, currently accounting for 10-20% of operated carcinomas (3). Prognosis after surgery is remarkably good with a 5-year survival rate reaching 95% . The overall incidence of lymph node metastasis is closely related to the depth of neoplastic invasion and, although extremely rare in mucosal carcinomas (0-7%), is approximately 19-23% in tumours extending to the submucosa (4-5). Gastrectomy with dissection of group 1 and group 2 lymph nodes (D2) is generally considered as the gold standard treatment for EGC, albeit the low incidence of lymph node metastasis, especially in mucosal carcinomas, has led numerous authors to question the practice of extended lymphadenectomy (6-7). Considerable attention has been drawn to the quality of life after surgery, with limited surgical procedures (e.g. endoscopic mucosal resection, local gastric resection and gastrectomy with D1 lymph node dissection) being developed in patients with EGC (8-9). The aim of this study is to investigate the incidence and clinicopathological predictors of nodal metastasis in order to plan a strategy for the treatment of EGC.

Patients and Methods

Between 1987 and 1992, a total of 841 patients underwent curative resection for gastric carcinoma at the University Hospital in Florence, Italy. Original pathology reports, discharge summaries and operative reports were reviewed to confirm patient age, gender, surgical resection, TNM stage, size, gross appearance and location of the tumour within the stomach.

Macroscopic classification was decided according to the criteria of the Japanese Society of Gastroenterological Endoscopy (10): the elevated type includes I, IIa, IIa + IIc and IIa + III lesions, while the depressed type includes IIc, III, IIc + III and IIc + IIa lesions. An experienced pathologist reviewed all sections of formalin-fixed and paraffin-embedded specimens stained with haematoxylin and eosin. Microscopic features were recorded according to the criteria of the Japanese Research Society for Gastric Cancer (JRSGC) classification in which differentiated carcinomas include papillary carcinomas and well to moderately differentiated tubular adenocarcinomas, while poorly differentiated carcinomas comprise poorly differentiated tubular adenocarcinomas and signet-ring cell carcinomas (10). The histological type of tumour was also determined according to the Laurén classification system (11). The Kodama classification was used to assess tumour size and growth pattern (12): the “super” or superficially spreading type is defined as a tumour measuring more than 4 cm in diameter, strictly confined to the mucosa (super-M) or focally infiltrating the submucosa (super-SM); the “small mucosal” type is a carcinoma less than 4 cm in diameter with or without minimal submucosal invasion, respectively small-SM and small-M; the “Pen” or penetrating variant is a lesion with a diameter under 4 cm, invading the submucosa in a penetrating fashion. The “Pen” type is further divided into two subgroups according to the pattern of invasion through the muscularis mucosae: the “Pen-A” tumours are characterised by expansive growth and complete destruction of the muscularis mucosae and the “Pen-B” tumours by infiltrative growth and fenestration of the muscularis mucosae. Involvement of regional lymph nodes was defined following the TNM classification of the International Union Against Cancer (UICC) (13).

Statistical analysis. By periodic linkage to Municipal Population Offices and to the Regional Mortality Registry, information was obtained for all patients regarding their survival. To eliminate bias due to operative deaths, patients who died within 30 days of surgery were excluded from the survival analysis. Survival rates were calculated according to the Kaplan-Meier method. The chi-square test for proportion was used to assess the association between clinicopathological parameters and lymph node involvement. Multivariate analysis regarding the prediction of lymph node metastasis was performed using logistic analysis. P-values of less than 0.05 were considered significant.

Results

In 116 out of 841 patients (13.8%) undergoing curative surgery for primary gastric carcinoma, the tumour was confined to the mucosa or submucosa. The study consisted of 69 males (59.5%) and 47 females (40.5%), with a ratio of 1.4:1. Patient age ranged from 37 to 89 years (mean age, 69.5 years). Total gastrectomy was performed on 30 patients (25.8%) and subtotal resection on 86 (74.2%). In all cases, dissection of group 1 and group 2 lymph nodes was carried out together with gastrectomy. Clinicopathological findings of the patients are detailed in Table I. Tumours were located in the upper third of the stomach in 8 cases (6.9%), in the middle third in 29 (25.0%) and in the lower third in 73 (62.9%). EGC was limited to the mucosa in 43 patients (37%) and extended to the submucosa in 73 (63%). Lymph node involvement was found in 11 patients (9.5%) and was always concomitant with submucosal invasion (Table II).

The correlation between the lymph node status and the other parameters showed that the maximal risk for nodal metastasis depended on tumour diameter, in particular over 3 cm (p=0.027), submucosal invasion (p=0.007), diffuse histotype (p=0.043), and Pen-A or Pen-B type according to Kodama (p=0.012). Conversely, age, gender, type of gastrectomy, tumour location and macroscopic appearance were unrelated to the incidence of lymph node metastasis (Table I).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Clinicopathological variables in patients with EGC according to the presence of lymph node metastasis.

On multivariate analysis, the diffuse type proved to be the only independent predictive factor of lymph node involvement, regardless of tumour size and growth pattern (OR=7.50; 95% CI=1.75-32.17; p=0.007).

Kaplan-Meier survival curves based on cause-specific mortality (Figure 1) did not significantly differ between node-negative and node-positive cases, with a 5-year observed survival of 88.8% and 81.8%, respectively (log-rank test: p=0.25), and a 10-year observed survival of 86.5% and 71.6%, respectively (log-rank test: p=0.18). In addition, the comparison of survival curves based on mortality from all causes did not significantly differ between the two groups of patients, with a 5-year observed survival of 78.1% and 72.7%, respectively (log-rank test: p=0.73), and a 10-year observed survival of 67.6% and 63.4%, respectively (log-rank test: p=0.80).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Clinicopathological findings of 11 patients with lymph node involvement.

Discussion

Recent developments in diagnosis and the introduction of mass screening programmes have led to an increase in the detection of EGC. Despite the fact that gastrectomy with D2 lymphadenectomy is generally considered to be the gold standard, the extent of lymph node dissection remains a controversial issue in the management of EGC (14-18).

The present study analysed the risk factors for the occurrence of lymph node metastasis in a large Western series of EGC treated at a single institution. An overall rate of lymph node metastasis of 9.5% was found. In other Western series, the probability of a primary gastric carcinoma confined to the mucosa or submucosa being associated with nodal metastasis varies from 7 to 18% (3).

Major risk factors for lymph node metastasis in EGC include large tumour size, lymphatic vessel involvement and submucosal invasion (19-23). In a survey of 748 patients, Sano et al. reported a significant difference (p<0.001) between the mean size of node-negative and node-positive carcinomas (24). Out of 239 tumours with a diameter of 2 cm or less, lymph node involvement was seen only in 6 cases, 5 of which were submucosal carcinomas. Hochwald et al. found that those tumours that were limited to the mucosa and under 4.5 cm in size had a 96% rate of negative nodes. In contrast, tumours having a diameter of 4.5 cm or more and penetrating the submucosa showed a 5.6% probability of positive nodes (25). Habu et al. demonstrated that there is a greater incidence of metastasis in protruding neoplasms which are larger than 4 cm and invade the submucosa (26). The presented results are in accordance with data from the literature. Indeed, tumour diameter exceeded 2 cm in all patients with nodal metastasis, with 6 cases of submucosal carcinoma (54.5%) measuring >3 cm in greatest dimension, while the remaining cases measured 2-3 cm. The 43 patients who had mucosal carcinomas did not show lymph node involvement, regardless of tumour dimension.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kaplan-Meier survival curves based on cause-specific mortality, stratified by nodal status.

In a multicentre study carried out by the JRSGC comprising 27,574 gastric carcinomas limited to the mucosa, 630 cases (2.8%) had lymph node metastases. Of the 630 neoplasms, 87.9% were of the depressed type (IIc, IIc+IIa, IIc+III). At histology, ulceration was found in 64.6% (10). Ulceration seems to facilitate lymph node dissemination, probably due to the breakdown of the muscularis mucosae increasing the chance of lymphatic vessel invasion by neoplastic cells. However, in submucosal tumours the rate of lymph node metastasis is similar whether ulceration is present or not (20-30% vs. 23-24%) (17). In this series, no difference was found in the distribution of macroscopic type.

Tumour growth pattern and vascular invasion have also been reported to be associated with lymph node metastasis. Data on record show that Super and Pen-B lesions have no tendency to vascular invasion, and only occasionally metastasise to lymph nodes (7.1% in Super-M; 15.2% in Super-SM; 7.7% in Pen-B), thus carrying a good prognosis with a 10-year survival rate of 90% (27). Pen-A type lesions, on the other hand, more often invade lymphatics (43.8% of cases) and veins (25%), and spread to regional lymph nodes (25%). Prognosis in such cases worsens, with a survival rate at 10 years falling to 64.8% (28). In this series, tumour type according to Kodama was observed as a risk factor in univariate analysis, with positive nodes being detected in only 9.1% of the non Pen-A submucosal tumours, but was not a significant risk factor in further multivariate analysis.

Data concerning the prognostic significance of histological type in EGC are contradictory. Although some researchers found that poorly differentiated cancers are significantly associated with a higher incidence of lymph node metastasis (20-21), others could not confirm these findings (22, 29). In this study, tumour histotype according to Laurén significantly predicted lymph node metastasis in multivariate analysis. High risk was particularly demonstrated for the diffuse type corresponding to the poorly differentiated type reported by Japanese authors.

In conclusion, with the increasing recognition of “good prognostic factors”, a recent trend in the treatment of EGC has been to limit surgery in order to optimise the patient's quality of life and achieve a complete cure. These results strongly suggest that minimally invasive surgical procedures, such as laparoscopic partial resection, are recommended in cases of submucosal gastric carcinoma with negligible risk of lymph node metastasis (intestinal type and under 2 cm in size).

  • Received October 20, 2008.
  • Revision received December 18, 2008.
  • Accepted January 27, 2009.
  • Copyright © 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Murakami T
    : Pathomorphological diagnosis. Definition and gross classification of early gastric cancer. Gann Monogr Cancer Res 11: 53-55, 1971.
    OpenUrl
  2. ↵
    1. Isozaki H,
    2. Tanaka N,
    3. Okajima K
    : General and specific prognostic factors of early gastric carcinoma treated with curative surgery. Hepatogastroenterology 46: 1800-1808, 1999.
    OpenUrlPubMed
  3. ↵
    1. Everett SM,
    2. Axon AT
    : Early gastric cancer in Europe. Gut 41: 142-150, 1997.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Inoue K,
    2. Tobe T,
    3. Kan N,
    4. Nio Y,
    5. Sakai M,
    6. Takeuchi E,
    7. Sugiyama T
    : Problems in the definition and treatment of early gastric cancer. Br J Surg 78: 818-821, 1991.
    OpenUrlPubMed
  5. ↵
    1. Yamao T,
    2. Shirao K,
    3. Ono H,
    4. Kondo H,
    5. Saito D,
    6. Yamaguchi H,
    7. Sasako M,
    8. Sano T,
    9. Ochiai A,
    10. Yoshida S
    : Risk factors for lymph node metastasis from intramucosal gastric carcinoma. Cancer 77: 602-606, 1996.
    OpenUrlPubMed
  6. ↵
    1. Park DJ,
    2. Lee HK,
    3. Lee HJ,
    4. Lee HS,
    5. Kim WH,
    6. Yang HK,
    7. Lee KU,
    8. Choe KJ
    : Lymph node metastasis in early gastric cancer with submucosal invasion: feasibility of minimally invasive surgery. World J Gastroenterol 10: 3549-3552, 2004.
    OpenUrlPubMed
  7. ↵
    1. Kunisaki C,
    2. Akiyama H,
    3. Nomura M,
    4. Matsuda G,
    5. Otsuka Y,
    6. Ono H,
    7. Nagahori Y,
    8. Hosoi H,
    9. Takahashi M,
    10. Kito F,
    11. Shimada H
    : Significance of long-term follow-up of early gastric cancer. Ann Surg Oncol 13: 363-369, 2006.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Yokota T,
    2. Saito T,
    3. Teshima S,
    4. Kikuchi S,
    5. Kunii Y,
    6. Yamauchi H
    : Lymph node metastasis in early gastric cancer: how can surgeon perform limited surgery? Int Surg 83: 287-290, 1998.
    OpenUrlPubMed
  9. ↵
    1. Nakamura K,
    2. Morisaki T,
    3. Sugitani A,
    4. Ogawa T,
    5. Uchiyama A,
    6. Kinukawa N,
    7. Tanaka M
    : An early gastric carcinoma treatment strategy based on analysis of lymph node metastasis. Cancer 85: 1500-1505, 1999.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Japanese Research Society for Gastric Cancer
    : The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 11: 127-145, 1981.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Laurén P
    : The two histological main types of gastric carcinoma. Diffuse and so-called intestinal-type. An attempt at histoclinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
    OpenUrlPubMed
  12. ↵
    1. Kodama Y,
    2. Inokuchi K,
    3. Soejima K,
    4. Matsusaka T,
    5. Okamura T
    : Growth patterns and prognosis in early gastric carcinoma. Superficially spreading and penetrating growth types. Cancer 51: 320-326, 1983.
    OpenUrlPubMed
  13. ↵
    1. American Joint Committee on Cancer
    : AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag Publisher, pp. 99-106, 2002.
  14. ↵
    1. Pacelli F,
    2. Doglietto GB,
    3. Bellantone R,
    4. Alfieri S,
    5. Sgadari A,
    6. Crucitti F
    : Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients. Br J Surg 80: 1153-1156, 1993.
    OpenUrlPubMed
    1. Siewert JR,
    2. Böttcher K,
    3. Roder JD,
    4. Busch R,
    5. Hermanek P,
    6. Meyer HJ
    : Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg 80: 1015-1018, 1993.
    OpenUrlPubMed
    1. Hartgrink HJ,
    2. van de Veldt CJ,
    3. Putter H,
    4. Bonenkamp JJ,
    5. Klein Frankenberg E,
    6. Songun I,
    7. Welvaart K,
    8. van Kraken JJ,
    9. Meier S,
    10. Plukker JT,
    11. van Elk JPL,
    12. Overtop H,
    13. Gouda DJ,
    14. van Ascot JJ,
    15. Tat COW,
    16. de Graf PAW,
    17. van Minefield MF,
    18. Tetanus H,
    19. Sasako M
    : Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22: 2069-2077, 2004.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Gotoda T,
    2. Sasako M,
    3. Ono H,
    4. Katai H,
    5. Sano T,
    6. Shimoda T
    : Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br J Surg 88: 444-449, 2001.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kunisaki C,
    2. Makino H,
    3. Akiyama H,
    4. Otsuka Y,
    5. Ono HA,
    6. Kosaka T,
    7. Takagawa R,
    8. Nagahori Y,
    9. Takahashi M,
    10. Kito F,
    11. Shimada H
    : Clinical significance of the metastatic lymph-node ratio in early gastric cancer. J Gastrointest Surg 12: 542-549, 2008.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Yasuda K,
    2. Shiraishi N,
    3. Suematsu T,
    4. Yamaguchi K,
    5. Adachi Y,
    6. Kitano S
    : Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma. Cancer 85: 2119-2123, 1999.
    OpenUrlPubMed
  18. ↵
    1. Wu CY,
    2. Chen JT,
    3. Chen GH,
    4. Yeh HZ
    : Lymph node metastasis in early gastric cancer: a clinicopathological analysis. Hepatogastroenterology 49: 1465-1468, 2002.
    OpenUrlPubMed
  19. ↵
    1. An JY,
    2. Baik YH,
    3. Choi MG,
    4. Noh JH,
    5. Sohn TS,
    6. Kim S
    : Predictive factors of lymph node metastasis in early gastric cancer with submucosal invasion. Analysis of a single institutional experience. Ann Surg 246: 749-53, 2007.
    OpenUrlPubMed
  20. ↵
    1. Son HJ,
    2. Song SY,
    3. Kim S,
    4. Noh JH,
    5. Sohn TS,
    6. Kim DS,
    7. Rhee JC
    : Characteristics of submucosal gastric carcinoma with lymph node metastatic disease. Histopathology 46: 158-165, 2005.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Roviello F,
    2. Rossi S,
    3. Marrelli D,
    4. Pedrazzani C,
    5. Corso G,
    6. Vindigni C,
    7. Morgagni P,
    8. Saragoni L,
    9. de Manzoni G,
    10. Tomezzoli A
    : Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol 94: 275-280, 2008.
    OpenUrl
  22. ↵
    1. Sano T,
    2. Kobori O,
    3. Muto T
    : Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg 79: 241-244, 1992.
    OpenUrlPubMed
  23. ↵
    1. Hochwald SN,
    2. Brennan MF,
    3. Klimstra DS,
    4. Kim S,
    5. Karpeh MS
    : Is lymphadenectomy necessary for early gastric cancer? Ann Surg Oncol 6: 664-670, 1999.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Habu H,
    2. Takeshita K,
    3. Sunagawa M,
    4. Endo M
    : Prognostic factors of early gastric cancer: results of long-term follow-up and analysis of recurrent cases. Jpn J Surg 17: 248-255, 1987.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Nishi M,
    2. Ichikawa H,
    3. Nakajima T,
    4. Maruyama K,
    5. Tahara E
    1. Inokuchi K,
    2. Sugimachi K
    : Growth patterns of gastric cancer. In: Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, editors. Gastric Cancer. Tokyo: Springer-Verlag Publisher, pp. 88-101, 1993.
  26. ↵
    1. Saragoni L,
    2. Gaudio M,
    3. Morgagni P,
    4. Folli S,
    5. Vio A,
    6. Scarpi E
    : The role of growth patterns, according to Kodama's classification, and lymph node status, as important prognostic factors in early gastric cancer: analysis of 412 cases. Gastric Cancer 3: 134-140, 2000.
    OpenUrlPubMed
  27. ↵
    1. Kurihara N,
    2. Kubota T,
    3. Otani Y,
    4. Ohgami M,
    5. Kumai K,
    6. Sugiura H,
    7. Kitajima M
    : Lymph node metastasis of early gastric cancer with submucosal invasion. Br J Surg 85: 835-839, 1998.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

In Vivo
Vol. 23, Issue 2
March-April 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pathological Predictors of Lymph Node Involvement in Submucosal Gastric Carcinoma: A Retrospective Analysis of Long-Term Outcome
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
14 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Pathological Predictors of Lymph Node Involvement in Submucosal Gastric Carcinoma: A Retrospective Analysis of Long-Term Outcome
GABRIELLA NESI, GIANCARLO BASILI, LUCIA ROBERTA GIRARDI, ANDREA MANETTI, GIANCARLO BILIOTTI, ALESSANDRO BARCHIELLI
In Vivo Mar 2009, 23 (2) 337-341;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Pathological Predictors of Lymph Node Involvement in Submucosal Gastric Carcinoma: A Retrospective Analysis of Long-Term Outcome
GABRIELLA NESI, GIANCARLO BASILI, LUCIA ROBERTA GIRARDI, ANDREA MANETTI, GIANCARLO BILIOTTI, ALESSANDRO BARCHIELLI
In Vivo Mar 2009, 23 (2) 337-341;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Distinct clinicopathological differences between early gastric cardiac and non-cardiac carcinomas: A single-center retrospective study of 329 radical resection cases
  • Upgrading the definition of early gastric cancer: better staging means more appropriate treatment
  • Google Scholar

More in this TOC Section

  • Efficacy of Percutaneous Direct Puncture Biopsy of Malignant Lung Tumors Contacting to the Pleura
  • Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies
  • Assessing the Risk of Stroke in the Elderly in the Context of Long-COVID, Followed Through the Lens of Family Medicine
Show more Clinical Studies

Similar Articles

In Vivo

© 2023 In Vivo

Powered by HighWire